Innoviva (INVA) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
UroGen Pharma (URGN) has outperformed Innoviva (INVA) over the past year, gaining 124.3% versus a gain of 21.5%. Over five years, URGN leads with a +116.4% price change compared with +27.7% for INVA. UroGen Pharma is the larger company by market cap ($1.80 billion vs $1.53 billion), about 1.2 times the size.
On valuation, Innoviva trades at a lower forward P/E (9.6x vs 13.2x for UroGen Pharma). Innoviva converts more of its revenue into profit, with a net margin of 65.9% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | URGN |
|---|---|---|
| Share price | $21.21 | $36.83 |
| Market cap | $1.53B | $1.80B |
| 1-day change | +1.63% | -0.41% |
| YTD return | +6.10% | +57.26% |
| 1-year return | +21.55% | +124.30% |
| 5-year return | +27.69% | +116.39% |
| P/E ratio (TTM) | 4.88 | — |
| Forward P/E | 9.60 | 13.18 |
| EPS (TTM) | $4.35 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $411.33M | $109.79M |
| Revenue growth (YoY) | +14.67% | +21.45% |
| Net income (latest FY) | $271.17M | $-153.49M |
| Gross margin | 74.80% | 88.66% |
| Operating margin | 39.81% | -113.73% |
| Net margin | 65.92% | -139.81% |
| 52-week high | $25.15 | $50.81 |
| 52-week low | $16.52 | $15.86 |
| Distance from 52-week high | -15.67% | -27.51% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +65.02% | +62.91% |
| Average volume | 789.55K | 849.01K |
| Shares outstanding | 72.25M | 48.88M |
| Employees | 159 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed INVA by 102.8 percentage points over the past year.
- Innoviva is more profitable, keeping 65.9 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs +14.67%).
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
INVA vs URGN FAQ
Which is bigger, Innoviva or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.80B compared with $1.53B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or URGN?
URGN returned +124.30% over the past 12 months, compared with +21.55% for INVA (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.